Recent News

• 06.09.2025 - IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
• 06.09.2025 - IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
• 06.02.2025 - IN8bio Company Presentation
• 06.02.2025 - IN8bio Company Presentation
• 06.02.2025 - IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
• 06.02.2025 - IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
• 05.14.2025 - IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025
• 05.14.2025 - IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025
• 05.12.2025 - IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products
• 05.12.2025 - IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

Recent Filings

• 06.04.2025 - 8-K Current report
• 06.02.2025 - 8-K Current report
• 06.02.2025 - EX-99.1 EX-99.1
• 05.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.09.2025 - 8-K Current report